National Institute Of Allergy And Infectious Diseases, Will Conduct A Trial Comparing The Administration Of Ocugen's Mucosal Vaccine Candidate, OCU500, Via Inhalation Into The Lungs And As Nasal Spray; Clinical Trials Scheduled To Start In Early 2024
Portfolio Pulse from Benzinga Newsdesk
The National Institute of Allergy and Infectious Diseases will conduct a trial comparing the administration of Ocugen's mucosal vaccine candidate, OCU500, via inhalation into the lungs and as nasal spray. The clinical trials are scheduled to start in early 2024. Ocugen is developing this novel anti-viral mucosal vaccine platform initially targeting COVID-19 and influenza.
October 10, 2023 | 10:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocugen's OCU500 vaccine will be tested by the National Institute of Allergy and Infectious Diseases. The trials, which will compare administration via inhalation and nasal spray, are set to start in 2024.
The news of the upcoming trial by a reputable institute could boost investor confidence in Ocugen, potentially leading to a short-term increase in the stock price. However, the impact may be somewhat mitigated by the fact that the trials are not scheduled to start until 2024.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100